Page 160 - Read Online

Sadaf et al. J Transl Genet Genom 2022;6:63-83 https://dx.doi.org/10.20517/jtgg.2021.36 Page 79

10. van Laar R, Flinchum R, Brown N, et al. Translating a gene expression signature for multiple myeloma prognosis into a robust high-
throughput assay for clinical use. BMC Med Genomics 2014;7:25. DOI PubMed PMC
11. Samo AA, Li J, Zhou M, et al. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome
inhibitor-based therapy. Genes Chromosomes Cancer 2018;57:420-9. DOI PubMed
12. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am
Soc Hematol Educ Program 2005;346-52. DOI PubMed
13. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-
8. DOI PubMed
14. Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014;2014:864058.
DOI PubMed PMC
15. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic
event in multiple myeloma. Blood 2005;106:296-303. DOI PubMed PMC
16. Clay-Gilmour AI, Hildebrandt MAT, Brown EE, et al. Coinherited genetics of multiple myeloma and its precursor, monoclonal
gammopathy of undetermined significance. Blood Adv 2020;4:2789-97. DOI PubMed PMC
17. Kristinsson SY, Björkholm M, Goldin LR, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree
relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 2009;125:2147-50. DOI PubMed PMC
18. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial risks and temporal incidence trends of multiple myeloma. Eur J
Cancer 2006;42:1661-70. DOI PubMed
19. Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with
multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114:785-90. DOI PubMed PMC
20. Morgan GJ, Johnson DC, Weinhold N, et al. Inherited genetic susceptibility to multiple myeloma. Leukemia 2014;28:518-24. DOI
PubMed
21. Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet
2011;44:58-61. DOI PubMed PMC
22. Koura DT, Langston AA. Inherited predisposition to multiple myeloma. Ther Adv Hematol 2013;4:291-7. DOI PubMed PMC
23. Chubb D, Weinhold N, Broderick P, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma
risk. Nat Genet 2013;45:1221-5. DOI PubMed PMC
24. Martino A, Campa D, Jamroziak K, et al. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple
myeloma. Br J Haematol 2012;158:805-9. DOI PubMed
25. Weinhold N, Johnson DC, Rawstron AC, et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.
Blood 2014;123:2513-7; quiz 2593. DOI PubMed
26. Ziv E, Dean E, Hu D, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma
patients. Nat Commun 2015;6:7539. DOI PubMed PMC
27. Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat
Commun 2016;7:12050. DOI PubMed PMC
28. Went M, Sud A, Försti A, et al; PRACTICAL consortium. Identification of multiple risk loci and regulatory mechanisms influencing
susceptibility to multiple myeloma. Nat Commun 2018;9:3707. DOI PubMed PMC
29. Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, et al. Germline variants at SOHLH2 influence multiple myeloma
risk. Blood Cancer J 2021;11:76. DOI PubMed PMC
30. Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various
ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009;23:1691-7. DOI PubMed
31. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy
of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012;26:609-14. DOI PubMed PMC
32. Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race,
and ethnicity in the United States. Blood Adv 2017;1:282-7. DOI PubMed PMC
33. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study.
Blood 2010;116:5501-6. DOI PubMed PMC
34. Du Z, Weinhold N, Song GC, et al. A meta-analysis of genome-wide association studies of multiple myeloma among men and
women of African ancestry. Blood Adv 2020;4:181-90. DOI PubMed PMC
35. Cozen W, Gebregziabher M, Conti DV, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and
plasmacytoma. Cancer Epidemiol Biomarkers Prev 2006;15:2285-91. DOI PubMed
36. Weinhold N, Meissner T, Johnson DC, et al. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific
regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica 2015;100:e110-3. DOI PubMed PMC
37. Li N, Johnson DC, Weinhold N, et al. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with
CDCA7L expression. Nat Commun 2016;7:13656. DOI PubMed PMC
38. Baughn LB, Pearce K, Larson D, et al. Differences in genomic abnormalities among African individuals with monoclonal
gammopathies using calculated ancestry. Blood Cancer J 2018;8:96. DOI PubMed PMC
39. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3
expression. Blood 2003;101:1520-9. DOI PubMed
40. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell
transplant. Br J Haematol 2004;125:64-8. DOI PubMed